Citadel Advisors
TNYA icon

Citadel Advisors’s Tenaya Therapeutics TNYA Stock Holding History

Citadel Advisors’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,100
Closed -$21.4K – 14238
2025
Q4 		$21.4K Buy
30,100
+18,100
+151% +$24.6K ﹤0.01% 12329
2025
Q3 		$19.4K Sell
12,000
-15,100
-56% -$15.2K ﹤0.01% 12494
2025
Q2 		$16.6K Sell
27,100
-51,300
-65% -$26.1K ﹤0.01% 12143
2025
Q1 		$44.7K Sell
78,400
-9,700
-11% -$9.57K ﹤0.01% 12427
2024
Q4 		$126K Buy
88,100
+87,700
+21,925% +$197K ﹤0.01% 11121
2024
Q3 		$772 Sell
400
-200
-33% -$565 ﹤0.01% 13958
2024
Q2 		$1.86K Sell
600
-500
-45% -$2.06K ﹤0.01% 13769
2024
Q1 		$5.75K Buy
+1,100
New +$5.26K ﹤0.01% 13724
2023
Q4 		– Sell
-700
Closed -$1.78K – 15267
2023
Q3 		$1.78K Sell
700
-4,500
-87% -$18.8K ﹤0.01% 13807
2023
Q2 		$30.5K Sell
5,200
-11,600
-69% -$67.4K ﹤0.01% 12338
2023
Q1 		$47.9K Sell
16,800
-19,300
-53% -$54.2K ﹤0.01% 12211
2022
Q4 		$72.6K Buy
36,100
+12,000
+50% +$29.3K ﹤0.01% 11655
2022
Q3 		$70K Buy
+24,100
New +$112K ﹤0.01% 11392

Other funds holding TNYA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Citadel Advisors's TNYA Position: Q1 2026 in Review

Citadel Advisors held its Tenaya Therapeutics (TNYA) position steady in Q1 2026 at 4,200,000 shares worth $2.91M. The position accounts for ﹤0.01% of the portfolio, ranked #5328.

Citadel Advisors first reported a position in TNYA in Q2 2022 and has held it in 14 quarters since. The position peaked at $11.8M in Q1 2024. 103 funds tracked by Wall St. Rank hold TNYA as of Q1 2026.

  • Citadel Advisors held 4,200,000 shares of Tenaya Therapeutics worth $2.91M as of Q1 2026.
  • Citadel Advisors left its Tenaya Therapeutics share count unchanged in Q1 2026.
  • Tenaya Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5328 holding.
  • Citadel Advisors first reported a position in Tenaya Therapeutics in Q2 2022 and has held it in 14 quarters since.
  • Citadel Advisors's Tenaya Therapeutics position peaked at $11.8M in Q1 2024.
  • 103 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.